Stock Performance - DaVita HealthCare (DVA) closed at $152 69, marking a +0 77% increase from the previous day [1] - The stock outperformed the S&P 500's daily loss of 1 11% and the Nasdaq's loss of 1 89% [1] - Over the past month, DVA shares depreciated by 4 13%, outperforming the Medical sector's loss of 6 22% but lagging the S&P 500's loss of 1 7% [1] Earnings and Revenue Expectations - The company is expected to report EPS of $2 21, up 18 18% from the prior-year quarter [2] - Revenue is predicted to be $3 25 billion, indicating a 3 47% increase compared to the same quarter of the previous year [2] Analyst Estimates and Revisions - Recent changes to analyst estimates reflect short-term business trends, with positive revisions indicating optimism about the company's outlook [3] - The Zacks Rank system, which considers estimate changes, currently rates DVA as a Zacks Rank 2 (Buy) [5] Valuation Metrics - DaVita HealthCare has a Forward P/E ratio of 13 48, indicating a discount compared to its industry's Forward P/E of 20 18 [5] - The PEG ratio is currently 0 74, lower than the industry average of 1 83, suggesting a favorable valuation relative to earnings growth [6] Industry Overview - The Medical - Outpatient and Home Healthcare industry has a Zacks Industry Rank of 87, placing it in the top 35% of all industries [7] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

DaVita HealthCare (DVA) closed the most recent trading day at $151.53, moving -0.84% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.55%. Elsewhere, the Dow saw a downswing of 0.06%, while the tech-heavy Nasdaq appreciated by 1.24%.The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. It is anticipated that the company will report an EPS of $2.21, marking a 18.18% rise compared to th ...

DaVita, Inc. (DVA) has witnessed strong momentum year to date. Its shares have risen 40.1% compared with the industry’s growth of 11.5%. The S&P 500 composite has gained 27.7% in the same period.DaVita, carrying a Zacks Rank #3 (Hold) at present, is witnessing an upward trend in its stock price, prompted by the company’s business model. The optimism, led by a decent third-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further.DaVita is a leading provider of dialy ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of FMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice ...

More than 8,300 people joined the annual event to raise funds for Bridge of LifeDENVER, Nov. 12, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced the success of its third annual Move It With Purpose (MIWP) event with more than 8,300 participants, including DaVita teammates, friends, family and key members of the kidney care community. The month-long initiative encourages physical activity — whether it's walking, running, swimming, bicycling or other activities — to be ...

DENVER, Nov. 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at UBS Global Healthcare Conference 2024 on Tuesday, November 12, 2024 at 12:30 pm PST (3:30 pm EST). To view the live webcast, visit the UBS page here and create a free registration.About DaVita Inc.DaVita (NYSE: DVA) is a health care provider focused on transforming c ...

The company's profitability is going in the wrong direction for many investors.Dialysis specialist DaVita (DVA -10.79%) had quite the Wednesday to forget, as investors sold out of its stock following the company's latest-earnings release. On the back of news that profitability was notably lower than expected, those folks left DaVita shares with a more-than 10% decline in value on the day. This was significantly worse than the 0.3% dip of the S&P 500 index that trading session.Revenue rose while profitabilit ...

Core Viewpoint - DaVita Inc. reported a decline in adjusted earnings per share (EPS) for Q3 2024, missing consensus estimates, despite an increase in revenues driven by higher reimbursement rates and other fluctuations [1][2][9][10]. Financial Performance - Adjusted EPS for Q3 2024 was $2.59, down 9.1% year over year, and missed the Zacks Consensus Estimate by 6.2% [1] - GAAP EPS for the quarter was $2.50, reflecting a decline of 4.6% year over year [1] - Revenues reached $3.26 billion, an increase of 4.6% year over year, surpassing the Zacks Consensus Estimate by 1.3% [2] - Gross profit rose 5.5% year over year to $1.11 billion, with a gross margin of 34.1%, expanding by 30 basis points [6] Revenue Breakdown - Dialysis patient service revenues were $3.14 billion, up 6.3% year over year [3] - Other revenues were $125 million, down 26.2% from the previous year [3] Operational Metrics - Total U.S. dialysis treatments for Q3 were 7,350,784, averaging 93,048 per day, which is a sequential decrease of 0.1% [4] - DaVita served approximately 265,400 patients at 3,113 outpatient dialysis centers as of September 30, 2024 [4] Strategic Developments - During Q3 2024, DaVita opened three and closed 15 dialysis centers in the U.S., while also acquiring one and opening four centers outside the U.S. [5] - The company had around 69,500 patients in risk-based integrated care arrangements, representing $5.4 billion in annualized medical spend [5] Margin and Cost Analysis - Adjusted operating profit totaled $718.2 million, reflecting a 6.1% increase from the prior year [6] - General & administrative expenses increased by 4.4% year over year to $393.5 million [6] Financial Position - DaVita ended Q3 2024 with cash and cash equivalents of $1.09 billion, up from $437.2 million at the end of Q2 [7] - Total debt at the end of Q3 was $9.56 billion, compared to $8.99 billion at the end of Q2 [7] - Cumulative net cash provided by operating activities was $1.47 billion, down from $1.57 billion a year ago [7] Future Outlook - DaVita reiterated its adjusted EPS guidance for 2024, projecting a range of $9.25-$10.05, with the Zacks Consensus Estimate at $9.99 [8]

DaVita Inc. (NYSE:DVA) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Nic Eliason - Group Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Andrew Mok - Barclays AJ Rice - UBS Pito Chickering - Deutsche Bank Lisa Clive - Bernstein Joanna Gajuk - Bank of America Ryan Langston - TD Cowen Justin Lake - Wolfe Research Operator Good evening. My name is Michelle and I will be your co ...

DaVita HealthCare (DVA) came out with quarterly earnings of $2.59 per share, missing the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $2.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.16%. A quarter ago, it was expected that this kidney dialysis provider would post earnings of $2.47 per share when it actually produced earnings of $2.59, delivering a surprise of 4.86%.Over the last four quart ...